- Emyria (EMD) receives positive screening results from its MDMA novel drug discovery program with the University of Western Australia (UWA)
- All 19 compounds sent from the third batch of compounds from the company’s MDMA analogue library successfully passed screening with Eurofins at the test concentrations
- Further, the tested compounds show no evidence of significant interactions with any enzymes or cell receptors associated with unwanted clinical side effects
- Based on the initial screening results, preclinical evaluations have commenced on a number of high priority compounds
- Shares in Emyria are up 11.8 per cent, trading at 28.5 cents at market close
Emyria (EMD) has received positive screening results from its MDMA novel drug discovery program with the University of Western Australia (UWA).
All 19 compounds sent from the third batch of compounds from the company’s MDMA analogue library successfully passed screening with Eurofins at the test concentrations.
Further, the tested compounds showed no evidence of significant interactions with any enzymes or cell receptors associated with unwanted clinical side effects.
Managing Director Dr Michael Winlo said the program has continued to make exciting forward progress.
“These latest positive screening results will help guide the creation of the next batch of novel MDMA-inspired compounds for our drug discovery portfolio,” he said.
“These results will also help inform which leads to advance to preclinical screening in our
three, high-priority areas; next generation psychedelic-assisted therapies as well as
potential treatments for unmet neurological and non-neurological conditions.”
The company said over 100 compounds have now been screened, with the results continuing to inform the drug design process.
Based on the initial screening results, preclinical evaluations have commenced on a number of high priority compounds selected.
Emyria also received approval from the US Drug Enforcement Agency (DEA) to transport five MDMA-analogues to America to engage with leading US-based research bodies and potential partners.
Subsequent to the DEA approval, the team at UWA have begun scaling up the synthesis of the five selected compounds to support further studies.
Shares in Emyria were up 11.8 per cent, trading at 28.5 cents at market close.